Evidence map›Paper›PMID 29470436›Full record

ReviewBrain sciences2018

Neurobiology of Propofol Addiction and Supportive Evidence: What Is the New Development?

Ming Xiong, Nimisha Shiwalkar, Kavya Reddy, Peter Shin, Alex Bekker

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ming XiongDepartment of Anesthesiology, New Jersey Medical School, Rutgers University, Newark, NJ 07107, USA. xiong@njms.rutgers.edu.
Nimisha ShiwalkarDepartment of Anesthesiology, New Jersey Medical School, Rutgers University, Newark, NJ 07107, USA. dr.nimisha4u@gmail.com.ORCID 0000-0003-1480-4301
Kavya ReddyDepartment of Anesthesiology, New Jersey Medical School, Rutgers University, Newark, NJ 07107, USA. kn268@njms.rutgers.edu.
Peter ShinDepartment of Anesthesiology, New Jersey Medical School, Rutgers University, Newark, NJ 07107, USA. shinpy@njms.rutgers.edu.
Alex BekkerDepartment of Anesthesiology, New Jersey Medical School, Rutgers University, Newark, NJ 07107, USA. bekkeray@njms.rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Propofol is a short-acting intravenous anesthetic agent suitable for induction and maintenance of general anesthesia as well as for procedural and intensive care unit sedation. As such it has become an unparalleled anesthetic agent of choice in many institutional and office practices. However, in addition to its idealistic properties as an anesthetic agent, there is accumulating evidence suggesting its potential for abuse. Clinical and experimental evidence has revealed that not only does propofol have the potential to be abused, but also that addiction to propofol shows a high mortality rate. Based on this evidence, different researchers have shown interest in determining the probability of propofol to be an addictive agent by comparing it with other drugs of abuse and depicting a functional similitude that involves the mesocorticolimbic pathway of addiction. In light of this, the Drug Enforcement Agency and the American Society of Anesthesiologists have put forth certain safety recommendations for the use of propofol. Despite this, the abuse potential of propofol has been challenged at different levels and therefore the preeminent focus will be to further validate the linkage from medicinal and occasional use of propofol to its addiction, as well as to explore the cellular and molecular targets involved in establishing this linkage, so as to curb the harm arising out of it. This review incorporates the clinical and biomolecular evidence supporting the abuse potential of propofol and brings forth the promising targets and the foreseeable mechanism causing the propofol addiction phenotypes, which can be called upon for future developments in this field.

Indexed as

abuse potentialfospropofolGABAA receptorglycine receptorpropofol

Identifiers

PMID29470436
PMCPMC5836055
OpenAlexW2790768198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.